Home News

ROVI completes the manufacture of the first batches of Moderna vaccine

Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the research, development and marketing of biological specialties and a manufacturer with a high degree of technological

Wed, 13/01/2021 - 17:03 0 min
Download related document
No votes yet
 
Related
Full Year 2021 Results Press Release
ROVI REPORTS OPERATING REVENUE GROWTH OF 54% AND NET PROFIT GROWTH OF 151% Operating revenue increased by 54% to 648.7 million euros...
2 min
23/02/2022
Moderna and ROVI expand long-term collaboration for the manufacture of mRNA...
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Laboratorios...
2 min
16/02/2022
ROVI receives the European Commission’s approval of Okedi® as a treatment for...
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the European Commission has authorised the...
3 min
15/02/2022